Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

soft tissue sarcoma

Daiichi Sankyo logo

Daiichi files new anticoagulant edoxaban in US and EU

Seeks approvals in atrial fibrillation and venous thromboembolism

- PMLiVE

FDA approves GSK’s combo cancer treatment

US regulator backs Mekinist and Tafinlar to treat melanoma

- PMLiVE

Lilly: 2014 will be “most financially challenging year”

Company still to feel worst effects of patent expiries

- PMLiVE

Disney and Lilly publish diabetes books online

Digital format for resource to help families with children who have type 1 diabetes

- PMLiVE

FDA to assess safety of Boehringer’s Pradaxa

US regulator plans study to compare the anticoagulant with warfarin

- PMLiVE

FDA backs a brace of allergy immunotherapies

Merck & Co and Stallergenes win drug approvals in US

- PMLiVE

First Cymbalta generics approved in the US

Lilly prepares for onslaught of competition for antidepressant

- PMLiVE

Senior hire for 3D Communications

Allison May Rosen joins as communications lead for FDA Advisory Committee projects

- PMLiVE

FDA panel backs Takeda’s inflammatory bowel disease drug

Vedolizumab on course for US approval to treat Crohn’s disease and ulcerative colitis

FDA reins in Google-backed genetics company 23andMe

Health-related genetic test service put on hold pending US regulatory review

- PMLiVE

Auxilium’s Xiaflex cleared in US for erection disorder

FDA approval to treat Peyronie's disease

- PMLiVE

Interview: Mike Hutton, Lilly

Lilly’s chief scientific officer for neurodegenerative diseases talks about his hopes for Alzheimer’s research and making the move from academia to pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links